Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q4 2023 vs. Q3 2023
How the institutions holding Silence Therapeutics plc changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 28 | 34 | +6 |
| Shares | 19.7M | 20.5M | +818.7K (+4.2%) |
| Value | $187.6M | $343.9M | +$156.3M (+83.4%) |
New holders (8)
Institutions that held Silence Therapeutics plc at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vivo Capital, LLC | 510,204 | $8.86M | 0.73% |
| Logos Global Management LP | 400,000 | $6.95M | 0.77% |
| Renaissance Technologies LLC | 27,102 | $471.0K | 0.00% |
| Citadel Advisors LLC | 21,737 | $377.6K | 0.00% |
| SG Americas Securities, LLC | 6,333 | $110.0K | 0.00% |
| GAMMA Investing LLC | 918 | $20.7K | 0.01% |
| Tower Research Capital LLC (TRC) | 707 | $12.3K | 0.00% |
| ADAR1 Capital Management, LLC | 190 | $3.30K | 0.00% |
Sold out (2)
Institutions that held Silence Therapeutics plc at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Goldman Sachs Group Inc | 266,667 | $2.62M |
| Deutsche Bank AG | 620 | $6.09K |